vs
Side-by-side financial comparison of INFINITY NATURAL RESOURCES, INC. (INR) and RHYTHM PHARMACEUTICALS, INC. (RYTM). Click either name above to swap in a different company.
INFINITY NATURAL RESOURCES, INC. is the larger business by last-quarter revenue ($115.5M vs $60.1M, roughly 1.9× RHYTHM PHARMACEUTICALS, INC.). INFINITY NATURAL RESOURCES, INC. runs the higher net margin — 17.3% vs -92.6%, a 109.9% gap on every dollar of revenue.
Rhythm Pharmaceuticals is a biopharmaceutical firm focused on developing and commercializing targeted therapies for rare genetic disorders causing severe unmanageable obesity, including POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome. It serves patients in North America and Europe who lack effective standard treatments for their chronic life-altering conditions.
INR vs RYTM — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $115.5M | $60.1M |
| Net Profit | $20.0M | $-55.6M |
| Gross Margin | — | 88.1% |
| Operating Margin | 47.0% | -87.1% |
| Net Margin | 17.3% | -92.6% |
| Revenue YoY | — | 83.8% |
| Net Profit YoY | — | — |
| EPS (diluted) | $1.33 | $-0.83 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $60.1M | ||
| Q4 25 | $115.5M | $57.3M | ||
| Q3 25 | $78.3M | $51.3M | ||
| Q2 25 | $72.5M | $48.5M | ||
| Q1 25 | $84.2M | $32.7M | ||
| Q4 24 | — | $41.8M | ||
| Q3 24 | — | $33.3M | ||
| Q2 24 | — | $29.1M |
| Q1 26 | — | $-55.6M | ||
| Q4 25 | $20.0M | $-47.5M | ||
| Q3 25 | $10.4M | $-52.9M | ||
| Q2 25 | $18.0M | $-46.6M | ||
| Q1 25 | $-34.6M | $-49.5M | ||
| Q4 24 | — | $-43.3M | ||
| Q3 24 | — | $-43.6M | ||
| Q2 24 | — | $-32.3M |
| Q1 26 | — | 88.1% | ||
| Q4 25 | — | 91.6% | ||
| Q3 25 | — | 89.3% | ||
| Q2 25 | — | 88.6% | ||
| Q1 25 | — | 88.8% | ||
| Q4 24 | — | 90.9% | ||
| Q3 24 | — | 88.5% | ||
| Q2 24 | — | 89.9% |
| Q1 26 | — | -87.1% | ||
| Q4 25 | 47.0% | -82.2% | ||
| Q3 25 | 30.5% | -102.6% | ||
| Q2 25 | 29.9% | -93.4% | ||
| Q1 25 | -104.5% | -143.7% | ||
| Q4 24 | — | -98.6% | ||
| Q3 24 | — | -132.0% | ||
| Q2 24 | — | -139.2% |
| Q1 26 | — | -92.6% | ||
| Q4 25 | 17.3% | -83.0% | ||
| Q3 25 | 13.3% | -103.1% | ||
| Q2 25 | 24.8% | -96.1% | ||
| Q1 25 | -41.1% | -151.4% | ||
| Q4 24 | — | -103.6% | ||
| Q3 24 | — | -131.2% | ||
| Q2 24 | — | -110.9% |
| Q1 26 | — | $-0.83 | ||
| Q4 25 | $1.33 | $-0.73 | ||
| Q3 25 | $0.65 | $-0.82 | ||
| Q2 25 | $1.18 | $-0.75 | ||
| Q1 25 | $-2.27 | $-0.81 | ||
| Q4 24 | — | $-0.71 | ||
| Q3 24 | — | $-0.73 | ||
| Q2 24 | — | $-0.55 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.8M | $340.6M |
| Total DebtLower is stronger | $55.0K | — |
| Stockholders' EquityBook value | $307.1M | $122.9M |
| Total Assets | $1.2B | $442.3M |
| Debt / EquityLower = less leverage | 0.00× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $340.6M | ||
| Q4 25 | $2.8M | $388.9M | ||
| Q3 25 | $4.6M | $416.1M | ||
| Q2 25 | $6.3M | $291.0M | ||
| Q1 25 | $4.9M | $314.5M | ||
| Q4 24 | — | $320.6M | ||
| Q3 24 | — | $298.4M | ||
| Q2 24 | — | $319.1M |
| Q1 26 | — | — | ||
| Q4 25 | $55.0K | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | $123.0K | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $122.9M | ||
| Q4 25 | $307.1M | $139.1M | ||
| Q3 25 | $288.6M | $148.8M | ||
| Q2 25 | $10.1M | $-11.9M | ||
| Q1 25 | $-52.2M | $18.9M | ||
| Q4 24 | — | $21.7M | ||
| Q3 24 | — | $11.2M | ||
| Q2 24 | — | $39.3M |
| Q1 26 | — | $442.3M | ||
| Q4 25 | $1.2B | $480.2M | ||
| Q3 25 | $1.1B | $506.9M | ||
| Q2 25 | $1.0B | $372.7M | ||
| Q1 25 | $953.9M | $386.7M | ||
| Q4 24 | — | $392.3M | ||
| Q3 24 | — | $363.6M | ||
| Q2 24 | — | $381.8M |
| Q1 26 | — | — | ||
| Q4 25 | 0.00× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $75.1M | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | 3.75× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $75.1M | $-25.4M | ||
| Q3 25 | $42.1M | $-26.6M | ||
| Q2 25 | $70.4M | $-23.3M | ||
| Q1 25 | $74.2M | $-40.4M | ||
| Q4 24 | — | $-18.8M | ||
| Q3 24 | — | $-25.2M | ||
| Q2 24 | — | $-29.1M |
| Q1 26 | — | — | ||
| Q4 25 | 3.75× | — | ||
| Q3 25 | 4.04× | — | ||
| Q2 25 | 3.91× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
INR
| Oil Reserves | $54.0M | 47% |
| Natural Gas Reserves | $46.8M | 41% |
| Natural Gas Liquids Reserves | $14.7M | 13% |
RYTM
Segment breakdown not available.
